X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Twelve months ago, the treasury team at Gilead Sciences, Inc., a fast-growing biopharmaceutical business that develops and produces treatments for some of the world’s deadliest diseases, faced some critical challenges. The company brings in close to $10 billion in annual revenue through operations in more than 30 countries. Yet its small treasury staff was spending more time on transaction processing than on analysis, and manual data entry put the company at risk for errors.

Dig Deeper

T&R Express

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2018 ALM Media Properties, LLC. All Rights Reserved.